RECURRENT GRADE 1 FOLLICULAR LYMPHOMA

This study tests a new treatment for people with high-risk B-cell non-Hodgkin lymphoma that has come back after initial therapy. Participants first receive a stem cell transplant, then get an infusion of their own immune cells that have been genetically modified to recognize and …

This study tests whether combining two immunotherapy drugs (rituximab and pembrolizumab) with or without a chemotherapy drug (lenalidomide) can shrink tumors in people whose follicular lymphoma or diffuse large B-cell lymphoma has returned after previous treatment. About 53 adult…

This early-stage trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have come back or not responded to treatment. The main goals are to find the best dose and check for side effects. The drug works by helping the immune system attack cance…

This early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …

This early-phase study tests a new immune therapy for people with high-risk or returning non-Hodgkin lymphoma. After a stem cell transplant, patients receive specially modified T-cells designed to find and attack cancer cells. The main goal is to check safety and find the best do…

This study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…

This study tests a drug called ibrutinib in 41 adults with follicular lymphoma that has come back or no longer responds to standard treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The main goal is to see how many patients have their tumors shr…

This early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and vorinostat (a drug that blocks enzymes cancer cells need to grow)—in 52 adults with certain types of lymphoma that had returned or stopped resp…

This study tests a combination of two drugs, nivolumab and lenalidomide, in people with non-Hodgkin or Hodgkin lymphoma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combination works at shrinking tumors. Ab…

This study is testing whether a combination of two drugs, epcoritamab and tazemetostat, is safe and effective for adults with follicular lymphoma that has come back or not responded to prior therapy. The drugs work together to help the immune system attack cancer cells and block …